Clinical Trial Search

Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — -0.61; -0.59; -0.10 percentage of Glycosylated Hemoglobin — p=<0.001

Primary: Disease Remission — 63; 52 Participants — p=<0.001

Primary: Annualized Number of Bleeding Episodes — 35.1; 4.6; 2.6 episodes — p=<0.0001

Primary: Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6 — -23.8; -27.1 mm — p=0.0085

Primary: Occurrence of Systemic and Local Adverse Events Following a Single or Repeat Intra-articular Injection of Gel-200 — 68; 43 participants — p=>0.1

Primary: Peak Inspiratory Capacity Assessed With Spirometry in the 4 Hours After Treatment — 2.705; 2.630; 2.557 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment — 1.49; 1.35 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day, Day 85) — 1.38; 1.26 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment — 2.50; 2.52; 2.59; 2.54 Liters

Primary: Percentage of Patients With at Least 1 Adverse Event During the 26 Weeks of the Study — 54.9; 66.4; 67.3 Percentage of patients

Primary: Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of…

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 2 + 1 Day, Day 15) — 1.35; 1.38; 1.38; 1.40 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12) — 1.44; 1.43 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment — 1.45; 1.39; 1.28 Liters

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) Assessed by Spirometry 24 Hour Post Dose After 12 Weeks of Treatment — 1.46; 1.46; 1.42; 1.28 Liters